İsrail - İbranice - Ministry of Health

roche pharmaceuticals (israel) ltd - pertuzumab; trastuzumab - תמיסה להזרקה - trastuzumab 40 mg/ml; pertuzumab 80 mg/ml - pertuzumab and trastuzumab

İsrail - İbranice - Ministry of Health

roche pharmaceuticals (israel) ltd - pertuzumab; trastuzumab - תמיסה להזרקה - trastuzumab 60 mg/ml; pertuzumab 60 mg/ml - pertuzumab and trastuzumab

İsrail - İbranice - Ministry of Health

roche pharmaceuticals (israel) ltd - satralizumab - תמיסה להזרקה - satralizumab 120 mg / 1 ml - satralizumab

İsrail - İbranice - Ministry of Health

roche pharmaceuticals (israel) ltd - pirfenidone - קפסולה קשיחה - pirfenidone 267 mg - pirfenidone

İsrail - İbranice - Ministry of Health

roche pharmaceuticals (israel) ltd - pirfenidone - קפסולה קשיחה - pirfenidone 267 mg - pirfenidone

İsrail - İbranice - Ministry of Health

roche pharmaceuticals (israel) ltd - ceftriaxone as sodium 1000 mg/vial - powder and solvent for solution for injection - ceftriaxone - long-acting, broad spectrum cephalosporin, for the treatment of infections caused by susceptible organisms.

İsrail - İbranice - Ministry of Health

roche pharmaceuticals (israel) ltd - ribavirin 200 mg - tablets - ribavirin - copegus in combination with peginterferon alfa 2a or interferon alfa - 2a is indicated in adult patients who are positive for serum hcv-rna, including patients with compensated cirrhosis . the combination with peginterferon alfa-2a is also indicated in patients co-infected with clinically stable hiv , including patients with compensated cirrhosis . copegus, in combination with peginterferon alfa-2a, is indicated in naive patients and patients who have failed previous treatment with interferon alpha (pegylated or non-pegylated) alone or in combination therapy with ribavirin.

İsrail - İbranice - Ministry of Health

tzamal bio-pharma ltd - ganciclovir sodium - תמיסה להזרקה - ganciclovir sodium 500 mg - ganciclovir - ganciclovir - cymevene iv is indicated for the treatment of cmv retinitis in immunocompromised patiens, including patients with acquired immunodeficiency syndrome (aids). cymevene iv is also indicated for the prevention of cmv disease in transplant recipients at risk for cmv disease.

İsrail - İbranice - Ministry of Health

roche pharmaceuticals (israel) ltd - trastuzumab - תמיסה לאינפוזיה - trastuzumab 440 mg/ml - trastuzumab - trastuzumab - herceptin is indicated for the treatment of patients with metastatic breast cancer who have tumours that overexpress her2: 1. as a single agent for the treatment of those patients who have received one or more chemotherapy regiments for their metastatic disease. 2. in combination with paclitaxel or docetaxel for the treatment of those patients who have not received chemotherapy for their metastatic disease. 3. herceptin in combination with an aromatase inhibitor for the treatment of postmenopausal patients with hormone-receptor positive metastatic breast cancer. early breast cancer (ebc) :herceptin is indicated to treat patients with her2-positive early breast cancer following surgery and chemotherapy (neoadjuvant or adjuvant) either alone or in combination with chemotherapy excluding anthracyclines. herceptin should only be used in patients whose tumors have either her2 overexpression or her2 gene amplification as determined by an accurate and validated assay.her2 metastatic gastric cancer (mgc)herceptin in

İsrail - İbranice - Ministry of Health

roche pharmaceuticals (israel) ltd - interferon alfa 2a 3 miu / 0.5 ml - solution for injection - interferon alfa-2a - condylumata acuminata. hepatitis b,c. hairy cell leukemia. cml. aids related kaposis sarcoma. renal cell carcinoma.follicular non-hodgkin's lymphoma. patients with ajcc stage ii malignant melanoma (breslow tumour thickness > 1.5 mm, no lymph node involvement or cutaneous spread) who are free of disease after surgery.